# OncoCipher Full Clinical Reference Index (https://patient.oncocipher.com) - Patient & Agent Base Portal: https://patient.oncocipher.com/ - Native MCP Streamable HTTP Server: https://patient.oncocipher.com/mcp - Clinician Portal: https://clinician.oncocipher.com/ - Research Portal: https://research.oncocipher.com/ ## Agent-Led Account Onboarding & Local PDF/Fax Folder Intake 1. `initiate_patient_account_onboarding(patient_email, display_name?, indication_hint?)` -> returns scoped `intake_upload_token` + patient claim URL. 2. `stage_patient_documents_and_notes(intake_id, files, patient_notes)` -> validates PDF/fax SHA-256 digests, checks deposit/MPP billing, and issues direct HTTP PUT URLs. 3. `finalize_intake_and_get_options_report(intake_id)` -> returns plain-language record summary, unranked FDA-label/guideline option categories, matched trials, oncologist visit checklist, and `https://patient.oncocipher.com/run/#overview`. ## Breast Cancer (`/cancers/breast` | module v5.0.0 | 64 options | 43 trials) Biomarker-guided reference covering hormone receptor (ER/PR), HER2 / HER2-low IHC/ISH, BRCA1/2, PIK3CA, AKT1/PTEN, ESR1, and recruiting clinical trials. - Option [Local care]: Breast and axillary surgery planning (sources: nci) - Option [Local care]: Postoperative radiation review (sources: nci) - Option [Endocrine therapy]: Adjuvant endocrine treatment (sources: nci) - Option [Endocrine therapy]: Preoperative aromatase inhibitor review (sources: nci) - Option [Chemotherapy]: Early chemotherapy review (sources: nci) - Option [Adjuvant targeted therapy]: Abemaciclib plus adjuvant endocrine therapy (sources: abema, abema_label, verzenio_coverage_20261109) - Option [Adjuvant targeted therapy]: Ribociclib plus adjuvant aromatase inhibitor (sources: ribo_adj, ribo_label, kisqali_coverage_20261109) - Option [Adjuvant targeted therapy]: Adjuvant olaparib (sources: olaparib) - Option [Neoadjuvant HER2 therapy]: T-DXd followed by taxane, trastuzumab and pertuzumab (sources: tdxd_early, enhertu) - Option [Neoadjuvant HER2 therapy]: Trastuzumab, pertuzumab and chemotherapy before surgery (sources: perjeta) - Option [Adjuvant HER2 therapy]: Trastuzumab, pertuzumab and adjuvant chemotherapy review (sources: perjeta) - Option [Post-neoadjuvant HER2 therapy]: T-DXd after residual invasive HER2-positive disease (sources: tdxd_early, enhertu) - Option [Perioperative TNBC therapy]: Pembrolizumab with chemotherapy, then postoperative pembrolizumab (sources: kn522_label, kn522, kn522_os) - Option [Post-neoadjuvant TNBC therapy]: Complete planned postoperative pembrolizumab (sources: kn522_label) - Option [Post-neoadjuvant chemotherapy]: Adjuvant capecitabine for residual TNBC (sources: createx, dpyd) - Option [Initial endocrine-based therapy]: Ribociclib plus an aromatase inhibitor (sources: ribo_label, kisqali_coverage_20261109) - Option [PI3K-directed therapy]: Inavolisib, palbociclib and fulvestrant (sources: inavo, inavo_label) - Option [AKT-directed therapy]: Capivasertib plus fulvestrant (sources: capi, capi_label, capi_label_i9) - Option [ESR1-directed endocrine therapy]: Elacestrant (sources: elacestrant, elacestrant_label) - Option [ESR1-directed endocrine therapy]: Vepdegestrant (sources: vep, vep_label) ## Non-Small Cell Lung Cancer (NSCLC) (`/cancers/lung` | module v5.0.0 | 92 options | 46 trials) Molecularly stratified reference covering EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, HER2, NTRK, PD-L1 expression, and recruiting trials. - Option [Local treatment]: Anatomic resection and nodal assessment (sources: nci_nsclc, calgb140503) - Option [Local treatment]: Definitive stereotactic radiation review (sources: nci_nsclc, rtog0236) - Option [Systemic therapy]: Perioperative pembrolizumab plus platinum chemotherapy (sources: peri_pembro, kn671_5y) - Option [Systemic therapy]: Perioperative nivolumab plus platinum chemotherapy (sources: peri_nivo, cm77t, cm77t_ctgov) - Option [Systemic therapy]: Perioperative durvalumab plus platinum chemotherapy (sources: peri_durva, aegean) - Option [Systemic therapy]: Adjuvant platinum-based chemotherapy (sources: nci_nsclc, lace) - Option [Systemic therapy]: Adjuvant osimertinib (sources: tagrisso, adaura, tagrisso_coverage_20261109) - Option [Systemic therapy]: Adjuvant alectinib (sources: adj_alectinib, alecensa, alina, alecensa_coverage_20261109, alina_ctgov, elevate_2026) - Option [Systemic therapy]: Adjuvant pembrolizumab after platinum (sources: adj_pembro) - Option [Systemic therapy]: Adjuvant atezolizumab after platinum (sources: adj_atezo) - Option [Systemic therapy]: Concurrent platinum chemoradiation (sources: nci_nsclc) - Option [Systemic therapy]: Sequential platinum chemoradiation (sources: nci_nsclc) - Option [Systemic therapy]: Durvalumab after concurrent chemoradiation (sources: imfinzi, pacific5) - Option [Systemic therapy]: Osimertinib after chemoradiation (sources: laura, laura_updated_2026) - Option [Systemic therapy]: Osimertinib (sources: tagrisso, flaura2_os, tagrisso_coverage_20261109) - Option [Systemic therapy]: Osimertinib plus platinum/pemetrexed (sources: osi_chemo, pemetrexed_label, flaura2_os) - Option [Systemic therapy]: Amivantamab plus lazertinib (sources: ami_laz, mariposa_os, rybrevant_faspro_spl) - Option [Systemic therapy]: Amivantamab plus carboplatin/pemetrexed after EGFR TKI (sources: ami_post, pemetrexed_label, rybrevant_faspro_spl) - Option [Systemic therapy]: Datopotamab deruxtecan after EGFR therapy and platinum (sources: dato) - Option [Systemic therapy]: Amivantamab plus carboplatin/pemetrexed (sources: ami_ex20, pemetrexed_label, rybrevant_faspro_spl) ## Colorectal Cancer (CRC) (`/cancers/crc` | module v2.0.0-nofda-prototype | 34 options | 507 trials) Source-cited reference covering MMR/MSI status, KRAS/NRAS, BRAF V600E, HER2 amplification, sidedness, surgical/systemic settings, and recruiting trials. - Option [care_pathway]: Stage 0/I colon local treatment review (sources: NCI-COLON) - Option [care_pathway]: Stage II colon observation discussion (sources: NCI-COLON, pdq_colon) - Option [conventional_therapy]: Stage II colon adjuvant risk/benefit review (sources: NCI-COLON, pdq_colon, FDA-DPD, FDA-XELODA-2025, xeloda) - Option [care_pathway]: Stage II dMMR colon specialist review (sources: NCI-COLON, pdq_colon) - Option [conventional_therapy]: Stage III colon FOLFOX / CAPOX review (sources: FDA-DPD, FDA-XELODA-2025, LABEL-OXALIPLATIN, NCI-COLON, pdq_colon, pm_29590544, pm_29611518, oxaliplatin) - Option [care_pathway]: Stage 0/I rectal local treatment review (sources: NCI-RECTAL) - Option [conventional_therapy]: Locally advanced rectal total neoadjuvant therapy review (sources: NCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738, pm_33301740, pm_33862000, FDA-DPD, FDA-XELODA-2025) - Option [care_pathway]: Lower-risk locally advanced rectal selective-radiation discussion (sources: NCI-RECTAL, pdq_rectal, pm_37272534, FDA-DPD, LABEL-OXALIPLATIN) - Option [biomarker_selected_therapy]: Dostarlimab (JEMPERLI) for MSI-H or dMMR stage II/III locally advanced rectal cancer (sources: LABEL-JEMPERLI-2026-10, pdq_rectal) - Option [care_pathway]: Rectal complete-response organ-preservation discussion (sources: NCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738) - Option [care_pathway]: Potentially curable metastatic local-treatment review (sources: NCI-COLON, pdq_colon, pdq_rectal) - Option [biomarker_selected_therapy]: Pembrolizumab first-line review (sources: FDA-PD1) - Option [biomarker_selected_therapy]: Nivolumab + ipilimumab review (sources: FDA-NIVO-IPI, opdivo) - Option [conventional_therapy]: FOLFOX / FOLFIRI + anti-VEGF review (sources: NCI-COLON, pdq_colon, avastin, FDA-DPD, FDA-XELODA-2025, LABEL-BEVACIZUMAB, LABEL-IRINOTECAN, LABEL-OXALIPLATIN) - Option [biomarker_selected_therapy]: Left-sided RAS/BRAF-wild-type doublet + anti-EGFR review (sources: NCI-COLON, pdq_colon, erbitux, vectibix, pm_35666229, FDA-DPD, FDA-XELODA-2025, LABEL-IRINOTECAN) - Option [biomarker_selected_therapy]: Encorafenib + cetuximab + fluorouracil-based chemotherapy review (sources: FDA-BRAF-2026, FDA-DPD, FDA-XELODA-2025, LABEL-BRAFTOVI-2026, LABEL-IRINOTECAN, LABEL-OXALIPLATIN) - Option [biomarker_selected_therapy]: Encorafenib + cetuximab after prior therapy (sources: FDA-BRAF-2026, FDA-DPD, LABEL-BRAFTOVI-2026) - Option [biomarker_selected_therapy]: Tucatinib + trastuzumab review (sources: FDA-HER2, LABEL-TUKYSA-2026-10) - Option [biomarker_selected_therapy]: Sotorasib + panitumumab review (sources: FDA-KRAS-SOTO) - Option [biomarker_selected_therapy]: Adagrasib + cetuximab — historical CRC indication (sources: FDA-KRAS-ADA, FDA-KRAS-ADA-WITHDRAWAL, LABEL-KRAZATI-2026-08, LABEL-KRAZATI-SPL-14) ## Ovarian, Fallopian Tube & Primary Peritoneal Cancer (`/cancers/ovarian` | module v6.0.0-nofda-prototype | 22 options | 342 trials) Source-cited reference covering germline/somatic BRCA1/2, HRD status, Folate Receptor-alpha (FRa), platinum interval, maintenance categories, and recruiting trials. - Option [selected_indicated_therapy]: Mirvetuximab soravtansine (sources: mirv, mirv-label) - Option [selected_indicated_therapy]: Pembrolizumab + paclitaxel ± bevacizumab (sources: pembro, pembro-label, paclitaxel-label, bev-label) - Option [selected_indicated_therapy]: Relacorilant + nab-paclitaxel (sources: rela, rela-label, nab-paclitaxel-label) - Option [conventional_therapy]: Paclitaxel (single agent) (sources: nci, paclitaxel-label) - Option [conventional_therapy]: Pegylated liposomal doxorubicin (single agent) (sources: nci, pld-label) - Option [conventional_therapy]: Topotecan (single agent) (sources: nci, topotecan-label) - Option [conventional_therapy]: Gemcitabine (single agent; off-label here) (sources: nci, gemcitabine-label) - Option [selected_indicated_therapy]: Bevacizumab + paclitaxel (sources: bev-label, nci, paclitaxel-label) - Option [selected_indicated_therapy]: Bevacizumab + pegylated liposomal doxorubicin (sources: bev-label, nci, pld-label) - Option [selected_indicated_therapy]: Bevacizumab + topotecan (sources: bev-label, nci, topotecan-label) - Option [selected_indicated_therapy]: Pembrolizumab alone (MSI-H or dMMR solid tumours) (sources: pembro-msi-label) - Option [selected_indicated_therapy]: Dostarlimab alone (dMMR solid tumours) (sources: jemperli-label-v15-selection, ventana-p210001-jemperli, mi-cancer-seek-p240010-jemperli, dostarlimab-label) - Option [selected_indicated_therapy]: Trastuzumab deruxtecan alone (HER2 IHC 3+ solid tumours) (sources: tdxd-label) - Option [care_pathway]: Clinical-trial review (sources: nci) - Option [care_pathway]: Supportive and palliative care review (sources: palliative) - Option [conventional_therapy]: Carboplatin + paclitaxel (platinum-sensitive recurrence; ICON4 / GOG-0213) (sources: carboplatin, paclitaxel, pm_12826431, pdq_ovarian) - Option [selected_indicated_therapy]: Carboplatin + paclitaxel + bevacizumab -> bevacizumab maintenance (GOG-0213) (sources: avastin, carboplatin, paclitaxel, pm_28438473, pdq_ovarian) - Option [selected_indicated_therapy]: Carboplatin + gemcitabine (platinum-sensitive recurrence >=6m; Study 1) (sources: gemcitabine, carboplatin, pdq_ovarian) - Option [selected_indicated_therapy]: Carboplatin + gemcitabine + bevacizumab -> bevacizumab maintenance (OCEANS / AVF4095g) (sources: avastin, gemcitabine, carboplatin, pm_22529265, pdq_ovarian) - Option [conventional_therapy]: Carboplatin + pegylated liposomal doxorubicin (CALYPSO) (sources: doxil, carboplatin, pdq_ovarian) ## Cutaneous & Mucosal Melanoma (`/cancers/melanoma` | module v6.0.0 | 36 options | 32 trials) Source-cited reference covering BRAF V600 status, NRAS/KIT, nodal staging, neoadjuvant/adjuvant and checkpoint/targeted therapy categories, and recruiting trials. - Option [Local care]: Surgery and regional-node staging review (sources: nci-melanoma, nci-melanoma-pdq-2025) - Option [Follow-up]: Post-resection surveillance discussion (sources: nci-melanoma) - Option [Systemic therapy]: Adjuvant pembrolizumab (sources: keytruda-label, keynote716, kn716-final, kn054-7y) - Option [Systemic therapy]: Adjuvant nivolumab (sources: opdivo-label, checkmate76k, checkmate238, cm76k-primary, cm238-9y, cm238-correction) - Option [Systemic therapy]: Adjuvant dabrafenib plus trametinib (sources: tafinlar-label, mekinist-spl, combiad-final) - Option [Specialist review]: Review discordant adjuvant BRAF V600K evidence (sources: tafinlar-label, combiad-final) - Option [Systemic therapy]: Neoadjuvant nivolumab plus ipilimumab, then response-guided review (sources: nadina, opdivo-label) - Option [Systemic therapy]: Perioperative pembrolizumab (sources: s1801, keytruda-label) - Option [Local care]: Upfront surgery followed by adjuvant-treatment review (sources: nci-melanoma, nadina, s1801) - Option [Systemic therapy]: Nivolumab plus ipilimumab (sources: opdivo-label, checkmate067-final, dreamseq, nct01844505) - Option [Systemic therapy]: Nivolumab plus relatlimab (sources: opdualag-label, relativity047) - Option [Systemic therapy]: Nivolumab monotherapy (sources: opdivo-label, checkmate067-final, relativity047, nct01844505) - Option [Systemic therapy]: Pembrolizumab monotherapy (sources: keytruda-label, kn006-10y, nct01866319) - Option [Systemic therapy]: Dabrafenib plus trametinib (sources: tafinlar-label, mekinist-spl, dreamseq) - Option [Systemic therapy]: Encorafenib plus binimetinib (sources: mektovi-label, braftovi-spl, mektovi-spl, columbus-7y) - Option [Systemic therapy]: Vemurafenib plus cobimetinib (sources: cotellic-label, zelboraf-spl, cobrim-5y) - Option [Systemic therapy]: Nivolumab plus ipilimumab after PD-1 progression (sources: opdivo-label, s1616) - Option [Systemic therapy]: Lifileucel cell-therapy referral (sources: amtagvi-fda, amtagvi-review, amtagvi-label) - Option [Local therapy]: Talimogene laherparepvec local treatment review (sources: imlygic-label) - Option [Specialist review]: Multidisciplinary CNS/local-therapy review (sources: nci-cns-pdq-2025, nci-melanoma-pdq-2025)